Peter Staib

20.3k total citations · 2 hit papers
135 papers, 5.8k citations indexed

About

Peter Staib is a scholar working on Epidemiology, Hematology and Infectious Diseases. According to data from OpenAlex, Peter Staib has authored 135 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Epidemiology, 36 papers in Hematology and 29 papers in Infectious Diseases. Recurrent topics in Peter Staib's work include Antifungal resistance and susceptibility (29 papers), Acute Myeloid Leukemia Research (26 papers) and Fungal Infections and Studies (23 papers). Peter Staib is often cited by papers focused on Antifungal resistance and susceptibility (29 papers), Acute Myeloid Leukemia Research (26 papers) and Fungal Infections and Studies (23 papers). Peter Staib collaborates with scholars based in Germany, Switzerland and United States. Peter Staib's co-authors include Joachim Morschhäuser, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger, Hubert Serve, Thomas Büchner, Michel Monod, Claudia Schoch, Wolfgang Hiddemann and Helmut Löffler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Peter Staib

131 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

2002 746 citations Susanne Schnittger, Wolfgang Kern et al. profile →
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Staib Germany	42	2.2k	1.8k	1.4k	1.2k	1.0k	135	5.8k
Gary J. Schiller United States	51	6.2k 2.8×	3.3k 1.8×	2.3k 1.6×	1.3k 1.1×	1.2k 1.1×	382	10.3k
Koji Kato Japan	34	2.2k 1.0×	584 0.3×	469 0.3×	1.0k 0.8×	469 0.5×	208	4.7k
Pier Luigi Tazzari Italy	49	1.6k 0.7×	3.6k 2.0×	1.6k 1.1×	409 0.3×	310 0.3×	256	8.0k
Günther Gastl Austria	38	959 0.4×	1.2k 0.7×	650 0.5×	809 0.7×	729 0.7×	137	4.3k
Suradej Hongeng Thailand	35	989 0.4×	1.6k 0.9×	1.1k 0.8×	352 0.3×	348 0.3×	318	4.7k
Kanjaksha Ghosh India	36	3.1k 1.4×	1.0k 0.6×	1.9k 1.4×	423 0.4×	362 0.3×	469	6.4k
Gösta Gahrton Sweden	52	4.1k 1.9×	2.6k 1.4×	2.3k 1.7×	898 0.7×	269 0.3×	268	8.3k
Richard Childs United States	57	4.6k 2.1×	2.3k 1.2×	1.5k 1.1×	804 0.7×	410 0.4×	273	10.7k
Nobuhiko Emi Japan	37	1.7k 0.8×	1.8k 1.0×	611 0.4×	291 0.2×	158 0.2×	170	4.3k
Robertson Parkman United States	44	2.7k 1.2×	1.3k 0.7×	713 0.5×	904 0.8×	357 0.3×	169	6.8k

Countries citing papers authored by Peter Staib

Since Specialization

Citations

This map shows the geographic impact of Peter Staib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Staib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Staib more than expected).

Fields of papers citing papers by Peter Staib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Staib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Staib. The network helps show where Peter Staib may publish in the future.

Co-authorship network of co-authors of Peter Staib

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Staib. A scholar is included among the top collaborators of Peter Staib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Staib. Peter Staib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loibl, S., Michael Untch, Jens Huober, et al.. (2025). 292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial. Annals of Oncology. 36. S303–S304. 1 indexed citations

Harbeck, Nadia, Ronald Kates, Timo Schinköthe, et al.. (2023). 195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. ESMO Open. 8(1). 101384–101384. 1 indexed citations

Dähnhardt, Dorothee, et al.. (2023). Improvement of Human Epidermal Barrier Structure and Lipid Profile in Xerotic- and Atopic-Prone Skin via Application of a Plant-Oil and Urea Containing pH 4.5 Emulsion. Cosmetics. 10(4). 95–95. 4 indexed citations

Dähnhardt, Dorothee, et al.. (2023). Protective and Regenerative Anti-Pollution Efficacy of a Plant Oil-Based Day and Night Cream: Investigated by a Novel Approach to Reveal the Impact of Pollutants on Epidermal Barrier Integrity and Lipid Matrix. Journal of Cosmetics Dermatological Sciences and Applications. 13(4). 302–321.

Harbeck, Nadia, Ronald Kates, Timo Schinköthe, et al.. (2023). Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. Cancer Treatment Reviews. 121. 102631–102631. 6 indexed citations

Denkert, Carsten, Andreas Schneeweiß, Julia Rey, et al.. (2022). Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers.. Journal of Clinical Oncology. 40(16_suppl). 583–583. 4 indexed citations

Loibl, Sibylle, Andreas Schneeweiß, Jens Huober, et al.. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Annals of Oncology. 33(11). 1149–1158. 136 indexed citations breakdown →

Schürer, Nanna, et al.. (2020). A Commercially Available Skin Care Lotion with a pH of 4.5 and 10% Urea Improves Skin Surface pH, Stratum Corneum Hydration and Epidermal Barrier Function in Subjects with Dry Skin and Atopic Diathesis. Journal of Cosmetics Dermatological Sciences and Applications. 10(3). 116–133. 2 indexed citations

Loibl, Sibylle, Bruno V. Sinn, Thomas Karn, et al.. (2019). Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.. Journal of Clinical Oncology. 37(15_suppl). 509–509. 8 indexed citations

10.

Staib, Peter, et al.. (2018). The Relation of pH and Skin Cleansing. Current problems in dermatology. 54. 132–142. 61 indexed citations

11.

Hofmann, Daniel, Ulrike Nitz, Oleg Gluz, et al.. (2013). WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 14(1). 261–261. 72 indexed citations

12.

Linde, Jörg, Ronny Martin, Bettina Böttcher, et al.. (2013). Global Transcriptome Sequencing Identifies Chlamydospore Specific Markers in Candida albicans and Candida dubliniensis. PLoS ONE. 8(4). e61940–e61940. 26 indexed citations

13.

Schwab, Matthias, Ulrike Kämmerer, Torsten Frambach, et al.. (2011). Seminal plasma protects human spermatozoa and pathogenic yeasts from capture by dendritic cells. Human Reproduction. 26(5). 987–999. 11 indexed citations

14.

Büchner, Thomas, Wolfgang E. Berdel, Claudia Haferlach, et al.. (2008). Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology. 27(1). 61–69. 232 indexed citations

15.

Schweighofer, Carmen D., Gerd Fätkenheuer, Peter Staib, Michael Hallek, & Marcel Reiser. (2007). Lyme Disease in a Patient with Chronic Lymphocytic Leukemia Mimics Leukemic Meningeosis. Oncology Research and Treatment. 30(11). 564–566. 4 indexed citations

16.

Staib, Peter, et al.. (2005). Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts. BMC Cancer. 5(1). 60–60. 4 indexed citations

17.

Reiser, Marcel, Andreas Josting, Mohammad Reza Soltani, et al.. (2002). T-cell Non-Hodgkin's Lymphoma in Adults: Clinicopathological Characteristics, Response to Treatment and Prognostic Factors. Leukemia & lymphoma. 43(4). 805–811. 41 indexed citations

18.

Staib, Peter, et al.. (2001). Gene regulation and host adaptation mechanisms in Candida albicans. International Journal of Medical Microbiology. 291(2). 183–188. 21 indexed citations

19.

Borchmann, Peter, R. Schnell, Jan Oliver Staak, et al.. (2001). Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma. Annals of Oncology. 12(5). 661–667. 44 indexed citations

20.

Staib, Peter, Axel Glasmacher, Achim Neufang, et al.. (1999). Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Annals of Hematology. 78(9). 418–425. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact